Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STAT EMENTS OF CASH FLOWS
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss attributable to Lineage | $(18,609) | $(21,486) |
| Net loss attributable to noncontrolling interest | 27 | 7 |
| Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities: | ||
| Issuance costs for common stock warrant liabilities | 688 | — |
| Loss on marketable equity securities, net | 8 | 176 |
| Accretion of income on marketable debt securities | (229) | (679) |
| Depreciation and amortization expense | 587 | 562 |
| Change in right-of-use assets and liabilities | (42) | 91 |
| Amortization of intangible assets | 22 | 130 |
| Stock-based compensation | 5,077 | 4,640 |
| Change in fair value of warrant liability | (2,128) | — |
| Deferred income tax benefit | — | (1,803) |
| Foreign currency remeasurement and other loss | 273 | 600 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 106 | (446) |
| Prepaid expenses and other current assets | 489 | (418) |
| Accounts payable and accrued liabilities | (1,681) | (2,295) |
| Deferred revenue | (7,680) | (7,645) |
| Net cash used in operating activities | (23,092) | (28,566) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from the sale of marketable equity securities | 18 | 196 |
| Purchases of marketable debt securities | (8,761) | (16,403) |
| Maturities of marketable debt securities | 7,000 | 63,330 |
| Purchase of equipment | (565) | (674) |
| Net cash (used in) provided by investing activities | (2,308) | 46,449 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from employee options exercised | 229 | 88 |
| Common shares received and retired for employee taxes paid | (23) | (37) |
| Proceeds from sale of common shares under ATM, net of offering costs | 68 | 6,426 |
| Proceeds from sale of common shares under registered direct financing, net of offering costs | 13,889 | — |
| Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs | 21,919 | — |
| Payment of financed insurance premium | (171) | — |
| Repayment of finance lease liabilities | (54) | (54) |
| Net cash provided by financing activities | 35,857 | 6,423 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (95) | (250) |
| NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 10,362 | 24,056 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||
| At beginning of the period | 35,992 | 11,936 |
| At end of the period | $46,354 | $35,992 |
| SUPPLEMENTAL DISCLOSURES: | ||
| Cash paid for interest | $9 | $10 |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: | ||
| Financing costs in accounts payable and accrued liabilities | $179 | $— |
| Fair value of warrant liability recognized upon issuance in registered direct financing | $8,289 | $— |
| Financed insurance premium | $855 | $— |
| Reconciliation of cash, cash equivalents and restricted cash, end of period: | ||
| Cash and cash equivalents | $45,789 | $35,442 |
| Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies)) | 565 | 550 |
| Total cash, cash equivalents, and restricted cash | $46,354 | $35,992 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.